• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用 RNA 脉冲树突状细胞生成同种异体限制性肽特异性 T 细胞：三阶段实验程序。

Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure.

机构信息

Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany.

出版信息

Oncoimmunology. 2012 Mar 1;1(2):129-140. doi: 10.4161/onci.1.2.18216.

DOI:10.4161/onci.1.2.18216
PMID:22720234
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3376998/
Abstract

Designer T cells expressing transgenic T cell receptors (TCR) with anti-tumor specificity offer new treatment options for cancer patients. We developed a three phase procedure to identify T cells of high avidity based on the fact that T cells recognizing peptides presented by allogeneic MHC efficiently kill tumor cells. Autologous dendritic cells (DC) are co-transfected with ivt-RNA encoding an allogeneic MHC molecule and a selected antigen to allow them to express allogeneic MHC-peptide complexes that activate allo-restricted peptide-specific T cells. This approach provides great flexibility for obtaining high-avidity T cells as potential sources of TCR for adoptive T cell therapy.

摘要

表达具有抗肿瘤特异性的转基因 T 细胞受体 (TCR) 的设计 T 细胞为癌症患者提供了新的治疗选择。我们开发了一种三阶段程序，根据 T 细胞识别由同种异体 MHC 呈递的肽能够有效杀伤肿瘤细胞的事实，来鉴定具有高亲和力的 T 细胞。自体树突状细胞 (DC) 与编码同种异体 MHC 分子和选定抗原的 ivt-RNA 共转染，以允许它们表达激活同种异体限制的肽特异性 T 细胞的同种异体 MHC-肽复合物。这种方法为获得高亲和力 T 细胞作为过继性 T 细胞治疗的 TCR 潜在来源提供了极大的灵活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/a1a90c32c4b6/onci-1-129-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/5526a3d95a01/onci-1-129-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/36f6235ef5ee/onci-1-129-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/89b80603b0de/onci-1-129-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/4e9165eb5b10/onci-1-129-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/a1a90c32c4b6/onci-1-129-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/5526a3d95a01/onci-1-129-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/36f6235ef5ee/onci-1-129-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/89b80603b0de/onci-1-129-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/4e9165eb5b10/onci-1-129-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3706/3376998/a1a90c32c4b6/onci-1-129-g5.jpg

相似文献

1
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure.使用 RNA 脉冲树突状细胞生成同种异体限制性肽特异性 T 细胞：三阶段实验程序。
Oncoimmunology. 2012 Mar 1;1(2):129-140. doi: 10.4161/onci.1.2.18216.
2
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.用编码同种异体主要组织相容性复合体（MHC）和抗原的RNA脉冲处理的树突状细胞可诱导具有卓越抗肿瘤活性和更高T细胞受体（TCR）功能亲和力的T细胞。
Blood. 2009 Sep 3;114(10):2131-9. doi: 10.1182/blood-2009-03-209387. Epub 2009 Jul 8.
3
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.用于抗肿瘤疫苗接种的自体与异体肽脉冲树突状细胞：异体主要组织相容性复合体的表达支持抗原特异性T细胞的激活，但会损害早期幼稚细胞毒性启动和抗肿瘤治疗。
Cancer Immunol Immunother. 2008 Jun;57(6):897-906. doi: 10.1007/s00262-007-0426-9. Epub 2007 Dec 4.
4
Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.经基因工程改造以表达特定同种异体 HLA 肽复合物的树突状细胞可有效诱导抗原特异性细胞毒性 T 细胞，从而高效杀伤肿瘤细胞。
Scand J Immunol. 2009 Apr;69(4):319-28. doi: 10.1111/j.1365-3083.2008.02223.x.
5
Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.利用源自CD34+造血祖细胞的逆转录病毒转导的树突状细胞产生针对肿瘤相关抗原HER2的肿瘤反应性细胞毒性T淋巴细胞。
J Immunol. 2000 Oct 1;165(7):4133-40. doi: 10.4049/jimmunol.165.7.4133.
6
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.为头颈部鳞状细胞癌的过继细胞转移生成新抗原特异性 T 细胞。
Oncoimmunology. 2021 May 25;10(1):1929726. doi: 10.1080/2162402X.2021.1929726.
7
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.外泌体作为有效的无细胞肽基疫苗。I. 树突状细胞衍生的外泌体将功能性MHC I类/肽复合物转移至树突状细胞。
J Immunol. 2004 Feb 15;172(4):2126-36. doi: 10.4049/jimmunol.172.4.2126.
8
Raising allo-restricted cytotoxic T lymphocytes by co-culture of murine splenocytes with autologous macrophage bearing the peptide/allo-major histococompatibility complex.通过将小鼠脾细胞与携带肽/同种异体主要组织相容性复合体的自体巨噬细胞共培养来培养同种异体限制性细胞毒性T淋巴细胞。
Hum Immunol. 2009 Feb;70(2):79-84. doi: 10.1016/j.humimm.2008.11.005. Epub 2008 Dec 25.
9
Avidity characterization of genetically engineered T-cells with novel and established approaches.采用新颖及既定方法对基因工程改造的T细胞进行亲和力表征。
BMC Immunol. 2016 Jul 13;17(1):23. doi: 10.1186/s12865-016-0162-z.
10
Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.使用全长肿瘤抗原mRNA电穿孔的抗原呈递肿瘤细胞系快速评估肿瘤特异性T细胞受体的功能亲和力
Cancers (Basel). 2020 Jan 21;12(2):256. doi: 10.3390/cancers12020256.

引用本文的文献

1
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.表达高效PRAME特异性T细胞受体并结合嵌合型PD1-41BB共刺激受体的T细胞显示出良好的临床前安全性和强大的抗肿瘤反应性。
Cancers (Basel). 2022 Apr 14;14(8):1998. doi: 10.3390/cancers14081998.
2
Genetic Modification of T Cells for the Immunotherapy of Cancer.用于癌症免疫治疗的T细胞基因改造
Vaccines (Basel). 2022 Mar 16;10(3):457. doi: 10.3390/vaccines10030457.
3
Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.

本文引用的文献

1
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.T 细胞受体基因修饰的 T 细胞具有共同的肾细胞癌特异性，用于过继性 T 细胞治疗。
Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.
2
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.癌症抗原的优先级排序：美国国立癌症研究所加速转化研究的试点项目
Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.
3
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.
试验观察：过继性T细胞受体工程化T细胞免疫疗法治疗急性髓系白血病
Cancers (Basel). 2021 Sep 8;13(18):4519. doi: 10.3390/cancers13184519.
4
Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.开发一种针对肿瘤相关抗原 MAGE-A4 的 CD8 共受体非依赖性 T 细胞受体，用于下一代基于 T 细胞的免疫治疗。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002035.
5
Enhancing adoptive T cell immunotherapy with microRNA therapeutics.用微小RNA疗法增强过继性T细胞免疫疗法。
Semin Immunol. 2016 Feb;28(1):45-53. doi: 10.1016/j.smim.2015.11.006. Epub 2015 Dec 20.
6
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.黑色素瘤：从无法治愈的“野兽”到可治愈的希望。免疫疗法的成功。
Front Oncol. 2015 Jul 13;5:152. doi: 10.3389/fonc.2015.00152. eCollection 2015.
7
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.T 细胞受体工程化 T 细胞在治疗实体瘤上面临新的挑战：抗原选择、T 细胞功能和肿瘤微环境的致敏。
Front Immunol. 2013 Nov 8;4:363. doi: 10.3389/fimmu.2013.00363. eCollection 2013.
8
Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity.通过MHC限制的自相残杀和TCR介导的造血干细胞毒性对TCR基因治疗的限制。
Oncoimmunology. 2013 Jan 1;2(1):e22410. doi: 10.4161/onci.22410.
用编码同种异体主要组织相容性复合体（MHC）和抗原的RNA脉冲处理的树突状细胞可诱导具有卓越抗肿瘤活性和更高T细胞受体（TCR）功能亲和力的T细胞。
Blood. 2009 Sep 3;114(10):2131-9. doi: 10.1182/blood-2009-03-209387. Epub 2009 Jul 8.
4
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.非清髓性异基因造血干细胞移植治疗慢性淋巴细胞白血病后肿瘤反应性T细胞的发育
Clin Cancer Res. 2009 Jul 15;15(14):4759-68. doi: 10.1158/1078-0432.CCR-09-0199. Epub 2009 Jun 30.
5
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.使用人类和小鼠T细胞受体的基因疗法介导癌症消退，并靶向表达同源抗原的正常组织。
Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.
6
Antigen choice in adoptive T-cell therapy of cancer.癌症过继性T细胞治疗中的抗原选择
Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Epub 2009 Mar 16.
7
Graft-versus-leukemia effects of transplantation and donor lymphocytes.移植及供体淋巴细胞的移植物抗白血病效应
Blood. 2008 Dec 1;112(12):4371-83. doi: 10.1182/blood-2008-03-077974.
8
Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.RNA文库复杂性对RNA脉冲树突状细胞刺激能力的抑制作用。
J Immunother. 2008 Jan;31(1):52-62. doi: 10.1097/CJI.0b013e31815a1202.
9
Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.异基因造血干细胞移植中同种异体反应性CD8 + T细胞反应的解剖与分子分析
Cancer Immunol Immunother. 2008 Jun;57(6):849-57. doi: 10.1007/s00262-007-0421-1. Epub 2007 Nov 15.
10
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.对FMNL1衍生肽PP2具有特异性的全限制性T细胞对血液系统和其他恶性肿瘤具有强大的抗肿瘤活性。
Blood. 2007 Oct 15;110(8):2931-9. doi: 10.1182/blood-2006-11-058750. Epub 2007 Jul 12.